COMMUNIQUÉS West-GlobeNewswire

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05/12/2025
BEDFORD, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has [...]
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
05/12/2025
Durable Glycemic and C-Peptide Improvements with Icovamenib in Insulin-Deficient Type 2 Diabetes SAN CARLOS, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) ( [...]
Iridex to Present at the Sidoti Year-End Virtual Investor Conference
05/12/2025
MOUNTAIN VIEW, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the [...]
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
05/12/2025
SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its [...]
Immatics Announces $125 Million Underwritten Offering
05/12/2025
Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision targeting of PRAME, [...]
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting
05/12/2025
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting Marseille, France, December 5, 2025 05:00 a.m. ET / 11:00 a.m. CET– ImCheck Therapeutics announced today an oral [...]
ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025
05/12/2025
Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development planned in this [...]
Ipsen provides update on legacy of Henri Beaufour
05/12/2025
PARIS, FRANCE, 5 December 2025, Ipsen (Euronext: IPN; ADR: IPSEY) has been informed that the shares of Beech Tree will be transferred to the Alasol Foundation, in accordance with the wishes of Mr. Henri Beaufour, Ipsen’ [...]
Ipsen apporte des précisions sur l'héritage d'Henri Beaufour
05/12/2025
PARIS, FRANCE, 5 décembre 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) a été informé que les actions de Beech Tree seront transférées à la Fondation Alasol, conformément aux souhaits de M. Henri Beaufour, membre du Conseil [...]
Protara Announces Pricing of $75 Million Public Offering
05/12/2025
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today [...]
Sapu Nano Announce Deciparticle™ Led Biomarker Framework Identifying Tumors Most Likely to Respond to IV Sapu003, an Intravenous Everolimus Nanomedicine
05/12/2025
San Diego, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- S apu Nano today announced new biomarker data identifying a molecular signature that predicts sensitivity to Sapu003 , the company’s intravenous Deciparticle ™ [...]
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
05/12/2025
Highly differentiated 1L EGFR PACC preliminary systemic activity of 80% ORR and 100% intracranial ORR, including in patients with active brain metastases 36% ORR in median 3L EGFR PACC patients exceeds competitor [...]
Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia
05/12/2025
Data showed encouraging results in patients with higher CLDN18.2 expression regardless of PD-L1 expression level, with a median PFS of 16.6 months, ORR of 68% and median DoR of 18 months PRINCETON, N.J. and SUZHOU, [...]
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA
05/12/2025
ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the [...]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04/12/2025
VANCOUVER, British Columbia and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, [...]
MEDIROM Mother Labs Partners with TD SYNNEX to Accelerate National Adoption of "MOTHER Bracelet" and "REMONY"
04/12/2025
TOKYO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) today announced that its subsidiary, MEDIROM MOTHER Labs Inc. (“MOTHER Labs”), which develops health-tech solutions [...]
Aveanna to Participate at the BofA Securities Home Care Conference
04/12/2025
ATLANTA, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the BofA Securities Home Care Conference virtually on December [...]
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
04/12/2025
Phase 2b trial showed significant improvements on primary and key secondary outcomes measures, most prominently in patients without AD co-pathology Significant reduction in key neurodegeneration biomarker correlated [...]
Stanford Medicine’s Dr. Pejman Ghanouni Receives RSNA’s Cum Laude Award for CAPTAIN Perioperative Data Presentation
04/12/2025
– CAPTAIN is the first randomized controlled trial ever comparing a new technology to the standard of care of robotic radical prostatectomy to successfully recruit to target – TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- [...]

Pages